Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 11/20 | 0.43 |
| ▸ | PPARA | Q07869 | 11/20 | 0.43 |
| ▸ | PPARD | Q03181 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4336800 | 0.91 | KMT2A (0.50) | SMN1; SMN2PPARGPPARAPPARDMEN1 | |
| SCHEMBL13810498 | 0.91 | KMT2A (0.50) | SMN1; SMN2PPARGPPARAPPARDMEN1 | |
| SCHEMBL4336806 | 0.91 | KMT2A (0.50) | SMN1; SMN2PPARGPPARAPPARDMEN1 | |
| SCHEMBL4334574 | 0.90 | PPARG (0.48) | PPARGPPARAPPARDMEN1KMT2A | |
| SCHEMBL4334564 | 0.90 | PPARG (0.48) | PPARGPPARAPPARDMEN1KMT2A | |
| SCHEMBL4334569 | 0.90 | PPARG (0.48) | PPARGPPARAPPARDMEN1KMT2A | |
| SCHEMBL4334186 | 0.90 | PPARA (0.48) | SMN1; SMN2PPARGPPARAPPARDTDP1 | |
| SCHEMBL4341681 | 0.89 | ADRB2 (0.50) | SMN1; SMN2PPARGPPARAPPARDMEN1 | |
| SCHEMBL4327647 | 0.88 | PPARG (0.44) | SMN1; SMN2PPARGPPARAPPARDTDP1 | |
| SCHEMBL4341897 | 0.88 | MEN1 (0.42) | PPARGPPARAPPARDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | SMN1; SMN2 3054/4885PPARG 379/4885PPARA 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.